Ipsen

Ipsen

Ipsen SA engages in the research, development, manufacture, and sale of pharmaceutical products worldwide.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
*
N/A

€500m

Post IPO Debt
Total Funding000k
No items found
No investors found

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2021202220232024202520262027
Revenues0000000000000000000000000000
% growth2 %15 %5 %8 %4 %6 %7 %
EBITDA0000000000000000000000000000
% EBITDA margin40 %38 %19 %38 %35 %35 %34 %
Profit0000000000000000000000000000
% profit margin24 %21 %19 %10 %17 %18 %19 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue15 %14 %19 %19 %---

Source: Company filings or news article, Equity research estimates

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo
Investments analysisEdit
  • Edit
Albireo
ACQUISITION by Ipsen Jan 2023
Clementia Pharmaceuticals
ACQUISITION by Ipsen Feb 2019
Tercica
ACQUISITION by Ipsen Jun 2008
Epizyme
ACQUISITION by Ipsen Jun 2022
Syntaxin
ACQUISITION by Ipsen Jul 2013
Canbex Therapeutics
ACQUISITION by Ipsen Feb 2015
OctreoPharm Sciences
ACQUISITION by Ipsen Jun 2015
View 3 more